Since symptoms such as fatigue and dyspnea are common to many heart and lung diseases, pulmonary hypertension often flies under the radar of respirologists and other health professionals.
In addition to their effects on type 2 diabetes, weight loss and colorectal cancer risk, glucagon-like peptide-1 receptor analogues may also act on nine other obesity-related cancers, reports a new study.